Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect
Don't underestimate this healthcare giant.
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.
Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.
Even in a recession, there's strong demand for J&J's myriad of pharmaceutical and healthcare products.
<![CDATA[M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD...
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC...
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a h...
Johnson & Johnson’s prostate cancer drug shrinks tumors in early-stage trial
Johnson & Johnson wins FDA approval for Rybrevant cancer treatment
Johnson & Johnson Stock Forecast & Price Predictions for 2026, 2027, 2028–2030 and Beyond
The Johnson & Johnson (JNJ) stock has long been a compelling asset thanks to the company's stability, reliability, and upside potential. Despite short-term corrections and mark...
J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
J&J earnings set ‘negative tone’; Shkreli vs. the FTC
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product...
Cerenovus Division
Cerenovus Division Anonymous (not verified) Sat, 09/26/2026 - 00:59 field_thread_url https://cafepharma.com/boards/threads/cerenovus-division.685354/...
Ex-Sales Leader Violated 'Secrecy' Pact, J&J Ortho Unit Says
Johnson & Johnson's orthopedic device unit DePuy Synthes alleged in New Jersey federal court that a former national sales leader's move to a rival violates several of his emplo...
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.
Medtronic is following a strategy that has worked well for Johnson & Johnson.
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient N...
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks com...
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease a...
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response...
Welcome to JnJ
Welcome to JnJ Anonymous (not verified) Mon, 10/12/2026 - 07:11 field_thread_url https://cafepharma.com/boards/threads/welcome-to-jnj.705944/...
J&J prostate cancer combination lowers PSA in small early study
J&J and Smith+Nephew Had a $34 Billion Ortho Deal on the Table. Then They Couldn’t Agree on a CEO.
Welcome to JnJ
Welcome to JnJ Anonymous (not verified) Tue, 10/13/2026 - 07:11 field_thread_url https://cafepharma.com/boards/threads/welcome-to-jnj.705944/...
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in a...
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activa...
Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.